CD47 and neoplasm: We found that targeting CD47, a macrophage checkpoint molecule, leads to anti-tumor activity via the induction of tumor cell phagocytosis and non-apoptotic cell death, providing an alternative therapeutic approach to adaptive immune checkpoint blockade strategies such as PD-1 and CTLA-4 inhibitors.